Management of Esophageal Squamous Cell Carcinoma with Definitive Chemoradiotherapy in a Patient with Scleroderma: Case Report and Review of the Literature
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Scleroderma is a disease characterized by fibrosis of the skin and internal organs, and is associated with changes in microvasculature. The association of scleroderma with malignancy has been debated, with early cohort studies showing no increase in the incidence of cancer among patients with scleroderma [1, 2]. Subsequent studies showed an increased incidence of lung cancer, breast cancer, esophageal cancer, oropharyngeal cancer, non-melanoma skin cancer, and lymphoproliferative malignancies in patients with scleroderma [2–9].
Both adenocarcinoma and squamous cell carcinoma of the esophagus have been described as occurring with increased incidence in patients with scleroderma . Patients with scleroderma are thought to have increased incidence of gastric reflux, development of Barrett’s esophagus, and subsequent development of esophageal adenocarcinoma, though this has not yet been validated in a prospective manner [11–13]. Overall, patients with scleroderma have a standar ...
- Farmer RG, Gifford Jr RW, Hines Jr EA. Prognostic significance of Raynaud's phenomenon and other clinical characteristics of systemic scleroderma. A study of 271 cases. Circulation. 1960;21:1088–95. CrossRef
- Duncan SC, Winkelmann RK. Cancer and scleroderma. Arch Dermatol. 1979;115(8):950–5. CrossRef
- Abu-Shakra M, Guillemin F, Lee P. Cancer in systemic sclerosis. Arthritis Rheum. 1993;36(4):460–4. CrossRef
- Chatterjee S, et al. Risk of malignancy in scleroderma: a population-based cohort study. Arthritis Rheum. 2005;52(8):2415–24. CrossRef
- Derk CT, et al. A cohort study of cancer incidence in systemic sclerosis. J Rheumatol. 2006;33(6):1113–6.
- Derk CT, et al. Increased incidence of carcinoma of the tongue in patients with systemic sclerosis. J Rheumatol. 2005;32(4):637–41.
- Peters-Golden M, et al. Incidence of lung cancer in systemic sclerosis. J Rheumatol. 1985;12(6):1136–9.
- Rosenthal AK, et al. Incidence of cancer among patients with systemic sclerosis. Cancer. 1995;76(5):910–4. CrossRef
- Roumm AD, Medsger Jr TA. Cancer and systemic sclerosis. An epidemiologic study. Arthritis Rheum. 1985;28(12):1336–40. CrossRef
- Ribeiro Jr U, et al. Risk factors for squamous cell carcinoma of the oesophagus. Br J Surg. 1996;83(9):1174–85. CrossRef
- Wipff J, et al. Prevalence of Barrett's esophagus in systemic sclerosis. Arthritis Rheum. 2005;52(9):2882–8. CrossRef
- Katzka DA, et al. Barrett's metaplasia and adenocarcinoma of the esophagus in scleroderma. Am J Med. 1987;82(1):46–52. CrossRef
- Marie I, et al. Oesophageal mucosal involvement in patients with systemic sclerosis receiving proton pump inhibitor therapy. Aliment Pharmacol Ther. 2006;24(11–12):1593–601. CrossRef
- Kang KY, et al. Incidence of cancer among patients with systemic sclerosis in Korea: results from a single centre. Scand J Rheumatol. 2009;38(4):299–303. CrossRef
- NCCN (version 2.2011) NCCN Clinical Practice Guidelines in Oncology: Esophageal and Esophagogastric Junction Cancers
- Morrow M, et al. Standard for breast conservation therapy in the management of invasive breast carcinoma. CA Cancer J Clin. 2002;52(5):277–300. CrossRef
- Gaast, A.V., et al., Effect of preoperative concurrent chemoradiotherapy on survival of patients with resectable esophageal or esophagogastric junction cancer: results from a multicenter randomized phase III study. J Clin Oncol, 2010. 28(15 s): p. suppl; abstr 4004.
- RTOG. RTOG/EORTC Late Radiation Morbidity Scoring Scheme. [2/18/2011]; Available from: www.rtog.org/members/toxicity/late.html.
- Varga J, et al. Exaggerated radiation-induced fibrosis in patients with systemic sclerosis. JAMA. 1991;265(24):3292–5. CrossRef
- Ross JG, et al. Acute and late reactions to radiation therapy in patients with collagen vascular diseases. Cancer. 1993;71(11):3744–52. CrossRef
- Morris MM, Powell SN. Irradiation in the setting of collagen vascular disease: acute and late complications. J Clin Oncol. 1997;15(7):2728–35.
- Gold DG, et al. Radiotherapy for malignancy in patients with scleroderma: the Mayo Clinic experience. Int J Radiat Oncol Biol Phys. 2007;67(2):559–67. CrossRef
- Lin A, et al. Toxicity of radiotherapy in patients with collagen vascular disease. Cancer. 2008;113(3):648–53. CrossRef
- Gold DG, et al. Chronic toxicity risk after radiotherapy for patients with systemic sclerosis (systemic scleroderma) or systemic lupus erythematosus: association with connective tissue disorder severity. Radiother Oncol. 2008;87(1):127–31. CrossRef
- Patel AA, et al. Implications of respiratory motion as measured by four-dimensional computed tomography for radiation treatment planning of esophageal cancer. Int J Radiat Oncol Biol Phys. 2009;74(1):290–6. CrossRef
- Vlachaki M, et al. Impact of respiratory gating using 4-dimensional computed tomography on the dosimetry of tumor and normal tissues in patients with thoracic malignancies. Am J Clin Oncol. 2009;32(3):262–8. CrossRef
- Management of Esophageal Squamous Cell Carcinoma with Definitive Chemoradiotherapy in a Patient with Scleroderma: Case Report and Review of the Literature
Journal of Gastrointestinal Cancer
Volume 43, Issue 1 Supplement, pp 156-160
- Cover Date
- Print ISSN
- Online ISSN
- Springer US
- Additional Links
- Industry Sectors
- Author Affiliations
- 1. Department of Radiation Oncology, Columbia University Medical Center—New York Presbyterian Hospital, New York, NY, USA
- 2. Department of Medicine, Columbia University Medical Center—New York Presbyterian Hospital, New York, NY, USA
- 3. Department of Surgery, Columbia University Medical Center—New York Presbyterian Hospital, New York, NY, USA
- 4. Department of Pathology, Columbia University Medical Center—New York Presbyterian Hospital, New York, NY, USA
- 5. Winter Park Cancer Center, Winter Park, FL, USA